New Zealand markets closed

Athira Pharma, Inc. (ATHA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.5600-0.0600 (-2.29%)
At close: 04:00PM EDT

Athira Pharma, Inc.

18706 North Creek Parkway
Suite 104
Bothell, WA 98011
United States
425 620 8501
https://www.athira.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees65

Key executives

NameTitlePayExercisedYear born
Dr. Mark J. Litton M.B.A., Ph.D.President, CEO & Director882.7kN/A1968
Mr. Andrew W. GengosCFO & Chief Business Officer396.16kN/A1964
Ms. Rachel P. Lenington M.B.A.Chief Development Officer & COO578kN/A1973
Dr. Kevin Church Ph.D.Chief Scientific Officer123.67kN/A1985
Ms. Julie RathbunHead of Investor RelationsN/AN/AN/A
Mr. Mark F. Worthington J.D.General Counsel & Corporate Secretary503.83kN/A1966
Ms. Samantha WillingChief People OfficerN/AN/AN/A
Dr. Javier San Martin M.D.Chief Medical OfficerN/AN/A1965
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Corporate governance

Athira Pharma, Inc.’s ISS governance QualityScore as of 1 May 2024 is 7. The pillar scores are Audit: 8; Board: 5; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.